Avvio Medical Proudly Announces ISO 13485 Certification, Marking a Major Milestone in Global MedTech Readiness
SAN FRANCISCO--(BUSINESS WIRE)-- Avvio Medical, Inc., a clinical-stage medical device company focused on transforming the treatment of kidney stone disease, is proud to announce that it has successfully achieved ISO 13485:2016 certification following its initial audit conducted by BSI (British Standards Institution). This globally recognized certification demonstrates Avvio's compliance with international standards for medical device quality management systems and reflects the company's unwavering commitment to excellence, patient safety, and operational rigor.
'This milestone is more than a regulatory requirement—it represents the fulfillment of our promise to stand up a full-scale medical device company,' said Paul Molloy, CEO of Avvio Medical. 'Through disciplined execution, a culture of continuous improvement, and a mindset grounded in honor, behavioral integrity, and precision, we have built a foundation for scalable, global operations.' He added, 'The quality culture at Avvio is not just a box-checking exercise. We embed it through storytelling, structured messaging, and principles drawn from disciplines of Lean and KAIZEN and a culture Bushidō. As we shared with the BSI audit team, our internal motto is #ImproveEverything—and this certification illustrates that we live by it.'
The ISO 13485 certification now enables Avvio to fully qualify its manufacturing and design processes for commercial scaling, pursue CE marking for international distribution, and reinforce confidence among global partners, investors, and regulators. The achievement is a major step toward the company's upcoming 2026 commercial launch in the U.S. market. With this certification, Avvio affirms that it is not only compliant—but built to lead.
About the Enhanced Lithotripsy System (ELS)
The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers.
About Avvio Medical
Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company's system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
ForSight Robotics raises $125M for cataract surgery platform
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. ForSight Robotics has raised $125 million as it prepares for first-in-human robotic cataract surgery clinical trials this year. The Israel-based company said this week the funds will support the next phase of growth in the development of its Oryom platform, the world's first robotic surgery platform for cataracts and other eye diseases. Participants in the Series B funding round include Eclipse, Intuitive Surgical co-founder Fred Moll, Adani Group and Reiya Ventures, among other investors. ForSight is scaling up, having identified a need to expand patient access to eye surgery amid a declining number of ophthalmologists and growing demand for vision treatment. The company cited a forecast from researchers at Vanderbilt University pointing to a 12% decline in ophthalmologists by 2035, alongside a projected 24% increase in demand. Joseph Nathan, ForSight co-founder and chief medical officer, said in a statement that the urgent global need presents an 'immense' opportunity for the company. 'We see ophthalmology as the next frontier in the robotics revolution – much like general surgery was before the rise of Intuitive Surgical,' said Nathan. Starting with cataract surgery, ForSight's platform aims to offer surgeons the dexterity, maneuverability and ergonomics to provide precise and consistent ophthalmic procedures, according to the company. The platform is designed to allow surgeons to navigate complex angles to reach any point in the eye, enabling glaucoma and retinal surgical treatment. 'The company is tapping into a massive, underserved market,' said Eclipse partner Seth Winterroth. ForSight said more than two dozen ophthalmic surgeons have successfully completed hundreds of procedures on animal eye models using its platform. In February, it received ISO 13485:2016 certification, an international benchmark for quality management systems in the medical device industry. The company completed a $55 million funding round in 2022, and has raised a total of $195 million to date. Recommended Reading 4 robotic surgery trends to watch in 2025 Sign in to access your portfolio
Associated Press
2 days ago
- Associated Press
Omdia Forecasts Flat TV Shipments in 2025, but Mini LED Poised for Explosive Growth at 82.9%
LONDON--(BUSINESS WIRE)--Jun 26, 2025-- Omdia's latest 1Q25 TV Sets Forecast reveals TV shipments are expected to remain nearly flat in 2025, totaling 208.7 million units (-0.1% year-on-year). Despite overall modest demand, Mini LED, and extra-large screen sizes are set to grow quickly, driven by retailers and brands focusing on premium features. This press release features multimedia. View the full release here: Year-on-Year (YoY) unit growth of TV shipments in 2024 and 2025 Omdia's latest TV sets analysis highlights two key regions expected to buck the global trend and deliver shipment growth in 2025: 'Although overall shipment growth remains flat, key technologies and larger screen sizes will see significantly higher growth rates. These differentiators will be crucial for both emerging Chinese brands and established players aiming to capture and defend market share,' explains Hisakazu Torii, Chief Analyst, TV Sets, Omdia. Top 5 positive YoY unit growth of TV technology, size, and features for 2025: Despite headwinds from US tariffs, North American shipments are expected to grow due to sufficient inventory built up since last year and aggressive pricing strategies from Chinese and channel brands. Overall shipments in North America will reach 49.9 million units in 2025, a 1.6% year-on-year unit growth. Consumers in this region benefit from a broad range of screen technologies, features, and brands offered at competitive prices. This diversity ensures a stable, accessible market environment, though it could become vulnerable if inventory tightens or prices rise significantly during the year. In China, shipments will reach 38.3 million units in 2025, a YoY growth rate of 3.2%, thanks to consumer electronics (CE) subsidies launched in August last year. While demand for larger screens (75-inch and above) continues to surge at 24.2% YoY, shipments for smaller screens (65-inch and below) are expected to decline 6.0% YoY. Strategic demand pull-in to drive inventory adjustments in Latin America TV shipments in Latin America experienced significant growth starting 4Q24 (15.2% YoY) and continuing into 1Q25 (9.2% YoY), prior to the announcement of US tariffs. The region had already enjoyed positive shipment momentum in the previous two years (2023-2024), supported by favorable currencies, stable inflation rates, strong economies, and lower unemployment rates. 'The recent spike in shipments, however, reflects growing concerns regarding potential negative impact of US tariffs. Retailers and brands have strategically accelerated shipments into the Latin America aiming to secure inventory earlier and at lower cost, particularly with the FIFA World Cup 2026 approaching next year,' said Torii. In the other regions (excluding North America, China and Latin America), shipments are expected to decline by -1.2% YoY in 2025. These markets lack strong promotional factors (such as major sporting events), face less aggressive pricing strategies, and continue to deal with inflation and currency volatility, and increased costs. ABOUT OMDIA Omdia, part of Informa TechTarget, Inc. (Nasdaq: TTGT), is a technology research and advisory group. Our deep knowledge of tech markets combined with our actionable insights empower organizations to make smart growth decisions. View source version on CONTACT: Media Contact: Fasiha Khan [email protected] KEYWORD: CHINA SOUTH AMERICA CENTRAL AMERICA NORTH AMERICA ASIA PACIFIC EUROPE UNITED STATES UNITED KINGDOM INDUSTRY KEYWORD: MOBILE/WIRELESS TECHNOLOGY TRANSPORT OTHER TECHNOLOGY AUDIO/VIDEO NETWORKS INTERNET HARDWARE LOGISTICS/SUPPLY CHAIN MANAGEMENT CONSUMER ELECTRONICS SOURCE: Omdia Copyright Business Wire 2025. PUB: 06/26/2025 07:17 AM/DISC: 06/26/2025 07:16 AM
Yahoo
2 days ago
- Yahoo
Avvio Medical Proudly Announces ISO 13485 Certification, Marking a Major Milestone in Global MedTech Readiness
SAN FRANCISCO, June 26, 2025--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company focused on transforming the treatment of kidney stone disease, is proud to announce that it has successfully achieved ISO 13485:2016 certification following its initial audit conducted by BSI (British Standards Institution). This globally recognized certification demonstrates Avvio's compliance with international standards for medical device quality management systems and reflects the company's unwavering commitment to excellence, patient safety, and operational rigor. "This milestone is more than a regulatory requirement—it represents the fulfillment of our promise to stand up a full-scale medical device company," said Paul Molloy, CEO of Avvio Medical. "Through disciplined execution, a culture of continuous improvement, and a mindset grounded in honor, behavioral integrity, and precision, we have built a foundation for scalable, global operations." He added, "The quality culture at Avvio is not just a box-checking exercise. We embed it through storytelling, structured messaging, and principles drawn from disciplines of Lean and KAIZEN and a culture Bushidō. As we shared with the BSI audit team, our internal motto is #ImproveEverything—and this certification illustrates that we live by it." The ISO 13485 certification now enables Avvio to fully qualify its manufacturing and design processes for commercial scaling, pursue CE marking for international distribution, and reinforce confidence among global partners, investors, and regulators. The achievement is a major step toward the company's upcoming 2026 commercial launch in the U.S. market. With this certification, Avvio affirms that it is not only compliant—but built to lead. About the Enhanced Lithotripsy System (ELS) The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers. About Avvio Medical Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company's system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals. View source version on Contacts Media Contact: Paul MolloyChief Executive OfficerAvvio Medical, Tel: (415) 887-2037
